Melanoma Research Alliance Announces Record $18.4 Million Investment, Targets the Next Frontier of Treatment

As we celebrate the start of Skin Cancer Awareness Month, the Melanoma Research Alliance (MRA) has announced a record $18.4 million global research investment aimed at accelerating the next generation of advances in melanoma detection and treatment.¹ The 2026 funding cycle represents the organization’s largest annual commitment to date and underscores the continued need for innovation as melanoma incidence rises worldwide.

This year’s portfolio includes 30 discovery-stage research grants distributed across leading academic and medical institutions in the US and 5 additional countries. In parallel, MRA is continuing to expand key collaborative infrastructure, including the RARE Melanoma Research Consortium and the Melanoma Biorepository. These initiatives are designed to address critical gaps in understanding rare and biologically complex melanoma subtypes by enabling data sharing, biospecimen access, and coordinated research efforts.

Melanoma remains the most lethal form of skin cancer, with more than 234,000 new cases projected globally in 2026, including approximately 112,000 invasive cases.² Although advances in early detection and systemic therapies have improved outcomes for some patients, disease incidence continues to increase. This trend highlights the need for sustained investment in both translational and early-stage research, particularly for patients who do not benefit from currently available therapies.

MORE ON MELANOMA

"Through the generosity of our supporters, MRA has been able to identify and fund high-impact research with great potential to contribute to life saving results," said MRA's Chief Executive Officer, Marc Hurlbert, PhD. "Since 2007 when MRA was founded, 19 FDA-approved treatments options have become available, and we are now building on that game-changing research looking at things from circadian immunodynamics to spatial and AI-powered insights and identifying new therapies as well as understanding drug resistance. Discovery is not always linear, but MRA's persistence has contributed to some exponential results that are transforming how cancer is treated overall."¹

The organization has outlined five strategic priority areas guiding its funding decisions:

• Rare melanomas, with a focus on understudied and difficult-to-treat subtypes such as acral, mucosal, pediatric, and uveal melanoma
• Metastasis and central nervous system involvement, particularly disease spread to the brain
• Therapeutic optimization, aimed at improving outcomes in both pre- and post-surgical settings
• Immune response innovation to enhance antitumor activity
• Diagnostics and biomarkers to support earlier detection and precision medicine.

MORE ON SKIN CANCER

A key emphasis of the 2026 investment is collaboration across disciplines and institutions. By integrating research efforts with resources such as the RARE Registry, a direct-to-patient data platform, and the expanding Melanoma Biorepository, these tools are expected to enhance the ability to study rare melanoma subtypes and support the development of more personalized treatment approaches.

Despite progress in the field, significant unmet needs in treatment remain. MRA’s funding strategy is designed to support high-impact research that can address resistance mechanisms, improve response rates, and expand therapeutic options. According to MRA’s Chief Science Officer, Joan Levy, PhD, approximately half of patients with advanced melanoma do not respond to existing therapies.

"This is a pivotal time for melanoma research and we are confident that the combination of world-class investigational research and the multidisciplinary resources now available through MRA's direct to patient RARE Registry, the newly formed RARE Melanoma Consortium and samples collected in the Melanoma Biorepository will synergize, leading to new and better disease options for personalized care," she said in the press release. "We have come a long way in the past 15 years, but we still have a long way to go...we are laser focused on finding new options through our exceptional grant program and other internal research initiatives."¹

References

1. Powering Progress: The Melanoma Research Alliance Announces $18.4 Million Global Research Investment to Accelerate the Next Era of Melanoma Breakthroughs. News release. PR Newswire. Published May 4, 2026. Accessed May 5, 2026. https://www.prnewswire.com/news-releases/powering-progress-the-melanoma-research-alliance-announces-18-4-million-global-research-investment-to-accelerate-the-next-era-of-melanoma-breakthroughs-302760896.html

2. American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf